Search Tag: ESC Congress 2019

Cardiology Management

#ESCCongress: New Management Pathways in Cardiovascular Risk Factors

2019 03 Sep

At the ESC Congress this year, several new guidelines have been released including updated guidelines on lipid control and new guidelines on diabetes and cardiovascular disease.  As per the updated guidelines on lipid control ,  the following are some key recommendations:  Low-density lipoprotein (LDL) cholesterol levels should be lowered... Read more

Cardiology Management

#ESCCongress: DAPA-HF Trial - Reduction in Cardiovascular Death, Hospitalisation

2019 01 Sep

The DAPA-HF study findings were presented today by Dr. John McMurray at the ESC Congress in Paris.  DAPA-HF is an international, multi-centre, parallel-group, randomised, double-blind trial in patients with heart failure and reduced ejection fraction (LVEF = 40%), with and without type-2 diabetes, designed to evaluate the effect of dapagliflozin,... Read more

Cardiology Management

#ESCCongress: THEMIS/THEMIS-PCI Findings - Minimal Benefits Observed

2019 01 Sep

Investigators from Brigham and Women's Hospital and Greater Paris University Hospitals - AP-HP/Université de Paris presented the results from The Effect of Ticagrelor on Health Outcomes in Diabetes Mellitus Patients Intervention Study (THEMIS) study at the ESC Congress in Paris.  The THEMIS trial evaluated whether adding ticagrelor to aspirin improved... Read more

Cardiology Management

#ESCCongress: Text Messages Help Patients with Diabetes - CHAT-DM Study

2019 31 Aug

New findings from the CHAT-DM study presented at the ESC Congress today report that text message intervention can result in better glycaemic control in patients with diabetes mellitus and coronary heart disease. Findings were just published in Circulation: Cardiovascular Quality and Outcomes.   According to the study author Dr. Xiqian Huo of... Read more

Cardiology Management

#ESCCongress: Findings from the EVOPACS Study

2019 31 Aug

Despite the fact that guidelines recommend the initiation of high-intensity statin therapy in patients with acute coronary syndrome (ACS), target levels are not achieved in a large number of patients. Evolocumab, a rapidly acting, low-density lipoprotein cholesterol (LDL-C) Lowering drug had so far not been studied in the acute phase of acute coronary... Read more

Cardiology Management

#ESCCongress: Cardiovascular Medicine Will Never Be The Same

2019 29 Aug

ESC Congress is the world’s largest gathering of cardiovascular professionals contributing to global awareness of the latest clinical trials and breakthrough discoveries. ESC Congress 2019 together with the World Congress of Cardiology takes place from 31 August to 4 September at the Expo Porte de Versailles in Paris, France. The  ESC Congress... Read more

Cardiology Management

#ESCCongress Preview: PARAGON-HF Trial

2019 10 Aug

Topline findings from the Phase III PARAGON-HF study have just been announced. Full results of the trial will be presented at the ESC Congress 2019 in September.  The  PARAGON-HF trial  in heart failure patients with preserved ejection fraction (HFPEF) investigates the safety and efficacy of sacubitril/valsartan versus the active comparator... Read more

Cardiology Management

#ESC2019 Preview: PARAGON-HF Trial

2019 03 Aug

Topline findings from the Phase III PARAGON-HF study have just been announced. Full results of the trial will be presented at the ESC Congress 2019 in September.  The PARAGON-HF trial in heart failure patients with preserved ejection fraction (HFPEF) investigates the safety and efficacy of sacubitril/valsartan versus the active comparator... Read more

Cardiology Management

ESC Congress 2019 together with World Congress of Cardiology (ESC-WCC 2019 - World Heart Federation)

2019 31 Aug

Find European Society of Cardiology on Social Media             Find WCC - World Heart Federation on Social Media      Read more